How Is Rhythm Pharmaceuticals Inc. (RYTM)’s Price-To-Earnings Ratio?

At the last check on Friday, Rhythm Pharmaceuticals Inc.’s (NASDAQ:RYTM) stock was up $1.17, moving up 6.29 percent to $19.76. The average number of shares traded per day over the past five days has been 1,944,724 shares. 5 times new highs have been achieved over the past 5 days, with a $7.10 gain in that time frame. In the last twenty days, the average volume was 4,857,771, while in the previous 50 days, it was 2,782,554.

Since last month, RYTM stock rose 292.19%. Shares of the company fell to $4.42 on 07/06/22, the lowest level in the past month. A 52-week high of $18.81 was reached on 08/05/22 after having rallying from a 52-week low of $3.04. Since the beginning of this year, RYTM’s stock price has risen by 86.27% or $9.72, and marked a new high 14 times. However, the stock has increased by 5.05% since its 52-week high.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Rhythm Pharmaceuticals Inc. (RYTM) last reported insider trading activity 9 days ago on Jul 27. Cramer Pamela J., the Chief Human Resources Officer of the company, disposed of 901 shares for $11.68 on Jul 27. It resulted in a $10,524 divestment by the insider. Smith Hunter C sold 7,547 shares at an average price of $4.08 on Jul 01. The insider now owns 57,614 shares following the transaction. On Mar 29, Chief Accounting Officer Roberts William T. sold 1,023 shares at $11.13 apiece. The transaction was valued at $11,386.

Valuation Metrics

The stock’s beta is 2.46. Besides these, the trailing price-to-sales (P/S) ratio of 190.55, the price-to-book (PB) ratio of 3.97.

Financial Health

In the three months ended June 29, Rhythm Pharmaceuticals Inc.’s quick ratio stood at 5.40, while its current ratio was 5.40, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 82.10% percent. Based on annual data, RYTM earned $2.56 million in gross profit and brought in $3.15 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -59.80%. Return on equity (ROE) for the past 12 months was -55.70%.

In Rhythm Pharmaceuticals Inc.’s quarter-end financial report for June 29, it reported total debt of $34.27 million against cash and short-term investments of $122.39 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. RYTM’s revenue rose 98.27% to $1.82 million during the quarter, while net income inched up to $2.31 million. While analysts expected Rhythm Pharmaceuticals Inc. to report -$0.95 quarterly earnings, the actual figure was -$0.89 per share, beating the consensus estimate by 6.30%. During the quarter, the company generated -$44.61 million in EBITDA. The liabilities of Rhythm Pharmaceuticals Inc. were 82.05 million at the end of its most recent quarter ended June 29, and its total debt was $2.26 million. The value of shareholders’ equity is $50.72 million.

Technical Picture

This quick technical analysis looks at Rhythm Pharmaceuticals Inc.’s (RYTM) price momentum. With a historical volatility rate of 215.57%, the RSI 9-day stood at 82.08% on 04 August.

With respect to its five-day moving average, the current Rhythm Pharmaceuticals Inc. price is up by +56.35% percent or $7.10. At present, RYTM shares trade +302.86% above its 20-day simple moving average and +109.35% percent above its 100-day simple moving average. However, the stock is currently trading approximately +486.31% above its SMA50 and +79.25% above its SMA200.

Stochastic coefficient K was 97.81% and Stochastic coefficient D was 88.55%, while ATR was 1.90. Given the Stochastic reading of 100.00% for the 14-day period, the RSI (14) reading has been calculated as 79.17%. As of today, the MACD Oscillator reading stands at 3.94, while the 14-day reading stands at 4.66.

Analyst Ratings

BofA Securities upgraded its rating on Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) to a Neutral in a note to investors on August 05, 2022. The analysts firm previously had an Underperform rating on the stock.Rhythm Pharmaceuticals Inc. (RYTM) has been rated Overweight by analysts. According to 0 brokerage firms, RYTM is a sell, and 2 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 0 analysts rate Rhythm Pharmaceuticals Inc. stock as buy, with 5 recommending it as overweight.

With a median target price of $25.00, the current consensus forecast for the stock is $6.00 – $40.00. Based on these forecasts, analysts predict Rhythm Pharmaceuticals Inc. (RYTM) will achieve an average price target of $24.00.


Please enter your comment!
Please enter your name here

Hot Topics

Related Articles